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The Journal of Immunology
Tissue-Resident NK Cells Mediate Ischemic Kidney Injury
and Are Not Depleted by Anti–Asialo-GM1 Antibody
Francisco Victorino,*,† Dorothy K. Sojka,‡ Kelley S. Brodsky,* Eoin N. McNamee,*
Joanne C. Masterson,x,{ Dirk Homann,*,1 Wayne M. Yokoyama,‡,‖ Holger K. Eltzschig,*
and Eric T. Clambey*
NK cells are innate lymphoid cells important for immune surveillance, identifying and responding to stress, infection, and/or
transformation. Whereas conventional NK (cNK) cells circulate systemically, many NK cells reside in tissues where they appear to
be poised to locally regulate tissue function. In the present study, we tested the contribution of tissue-resident NK (trNK) cells to
tissue homeostasis by studying ischemic injury in the mouse kidney. Parabiosis experiments demonstrate that the kidney contains
a significant fraction of trNK cells under homeostatic conditions. Kidney trNK cells developed independent of NFIL3 and T-bet,
and they expressed a distinct cell surface phenotype as compared with cNK cells. Among these, trNK cells had reduced asialo-
GM1 (AsGM1) expression relative to cNK cells, a phenotype observed in trNK cells across multiple organs and mouse strains.
Strikingly, anti–AsGM1 Ab treatment, commonly used as an NK cell–depleting regimen, resulted in a robust and selective
depletion of cNKs, leaving trNKs largely intact. Using this differential depletion, we tested the relative contribution of cNK
and trNK cells in ischemic kidney injury. Whereas anti–NK1.1 Ab effectively depleted both trNK and cNK cells and protected
against ischemic/reperfusion injury, anti–AsGM1 Ab preferentially depleted cNK cells and failed to protect against injury. These
data demonstrate unanticipated specificity of anti–AsGM1 Ab depletion on NK cell subsets and reveal a new approach to study the
contributions of cNK and trNK cells in vivo. In total, these data demonstrate that trNK cells play a key role in modulating local
responses to ischemic tissue injury in the kidney and potentially other organs. The Journal of Immunology, 2015, 195: 4973–4985.
N
atural killer cells are rapidly responding lymphoid cells
that have a central role in local and systemic immune
surveillance. NK cell recognition and activation are
mediated through engagement of multiple activating and inhibitory
receptors, broadly referred to as NKRs, with the relative engage-
ment of inhibitory and activating receptors influencing whether a
cell is protected from, or becomes a target for, NK cell destruction
(1–5). The specificity and sensitivity of NK cell recognition are
thought to be initially acquired in the bone marrow and further
refined in the periphery, a process known as education and li-
censing (6–10). Upon activation, NK cells can profoundly shape
the immune response via cognate and noncognate interactions,
rapidly producing cytokines, chemokines, and/or directly inducing
cell death (e.g., by perforin/granzyme-mediated apoptotic induc-
tion within target cells) (4, 11–14).
Genetic models have provided insights into NK cell development
and their role as potent regulators of inflammation and immunity
(15–21). However, given that many genetic models of NK cell
deficiency are compounded by additional defects, studies often
investigate the role of NK cells using Ab depletion methods.
In vivo depletion studies of NK cells have been primarily done
using 1) Abs to NK1.1, a glycoprotein expressed on NK cells and
subsets of gd T, NKT, and CD8 T cells in certain strains of mice;
or 2) Abs to asialo-GM1 (AsGM1), a glycolipid highly expressed
on NK cells, basophils, and subsets of gd T, NKT, and CD8 T cells
(22). Whereas anti–NK1.1 Ab depletion using the PK136 Ab
clone works robustly in some strains of mice (e.g., C57BL/6J
[B6], SJL, and NZB), this Ab does not work in other strains of
mice due to allelic variation in the NKR-P1 gene that encodes
NK1.1 (CD161) (23, 24). In contrast, anti–AsGM1 Ab robustly
depletes NK cells across multiple strains of mice, including B6,
BALB/c, DBA2, and 129S1/SvImJ (129) strains, and it remains in
use to this day (22, 25, 26).
Although NK cells were once considered to be a functionally
homogeneous lymphocyte population (e.g., in contrast to the di-
versity of specificities and functionalities of T cells), there is now
clear evidence that NK cells have the capacity to discriminate be-
tween diverse targets and to respond with diverse functions (27–36).
In attempts to better understand this NK cell diversity, NK cells
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have been divided into subsets based on heterogeneous expression
of various cell surface markers (e.g., TRAIL, Thy1, KLRG1, CCR2,
CD11b, and CD27) or divergent functional properties (37–41).
Recently, liver NK cells were shown to contain two distinct subsets,
tissue-resident NK (trNK) cells and conventional NK (cNK), cir-
culating cells, based on differences in trafficking and tissue reten-
tion (42). Notably, further studies demonstrated that beyond these
differences in trafficking, trNK and cNK cells have differences in
cytokine production, cell surface proteins involved in cell adhesion
and NK cell recognition, and distinct developmental requirements
(43). Whereas the contribution of trNK cells to shaping immune
responses remains an active area of investigation, liver trNK cells
are known to confer memory-like immune responses in a contact
hypersensitivity model (42). The existence of both local and sys-
temic NK cell reservoirs has significant implications in under-
standing the multifaceted role of NK cells in regulating local and
systemic immune responses.
In this study, we sought to investigate the characteristics and
contribution of trNK cells to local tissue injury in the context of
ischemia/reperfusion injury (IRI). To study the role of NK cells in
IRI, we used a mouse model of ischemic acute kidney injury (AKI),
a common human pathology characterized by ischemia that can
result from various etiologies, including diabetes, major surgery,
sepsis, and drug toxicity (44). Although several previous studies
have highlighted the importance of NK cells in ischemic AKI
using patch-clamping models of AKI (45–47), the role of NK cells
in ischemic AKI in the absence of intrarenal coagulation remain
unknown. Notably, the dynamics and contributions of cNK and
trNK cells in ischemic tissue injury remain undefined.
By studying trNK cells in the kidney, as well as in multiple other
organs, we found that trNK cells have variable and reduced AsGM1
expression relative to cNK cells, such that trNK cells are relatively
spared from depletion by anti–AsGM1 Abs. Using this knowledge,
we demonstrate that trNK cells are a potent mediator of IRI. These
data identify a new method to study trNK cells in vivo and define
a new physiological role for trNK cells as a front-line player in the
response to acute ischemic injury.
Materials and Methods
Mice
B6, NOD/ShiLtJ (NOD), BALB/c (BALB/cJ), 129, and CD1d-deficient
(CD1dKO; formerly named B6.129S6-Cd1d1/Cd1d2tm1Spb/J) mice were
purchased from The Jackson Laboratory (Bar Harbor, ME) and briefly
housed in a specific pathogen-free colony at the University of Colorado,
Anschutz Medical Campus. CD1dKO (a gift from Dr. Laurent Gapin,
University of Colorado, Anschutz Medical Campus) (48), B6, and BALB/c
mice were also obtained from breeding colonies at the University of
Colorado, Anschutz Medical Campus and maintained in a pathogen-free
facility and were of 8–12 wk of age for experimental use. Mice were age
and sex matched for experiments, with male mice uniformly used for
general screening and IRI studies. Female mice were solely used for the
analysis of trNK cell distribution in multiple organs. All experiments were
approved by the Institutional Animal Care and Use Committee of the
University of Colorado Denver, in accordance with the National Institutes
of Health guidelines for use of live animals. The University of Colorado
Denver, Anschutz Medical Campus is accredited by the American As-
sociation for the Accreditation of Laboratory Animal Care. Tbet2/2
(formal gene name Tbx21) mice were purchased from The Jackson
Laboratory and NFIL-32/2 mice (from Paul B. Rothman, Johns Hopkins
University) (43, 49) were bred and housed in a pathogen-free facility,
with procedures performed in accordance with the animal protocol ap-
proved by the Washington University School of Medicine Animal Studies
Committee.
Induction of IRI
The hanging weight system was used as previously described (50). Briefly,
mice were anesthetized with pentobarbital at 20 mg/kg and body tem-
perature was regulated using an anal probe during the entire surgery. For
sham surgery, mice were subjected to a right kidney nephrectomy followed
by recovery under a heat lamp. To induce IRI, nephrectomy of the right
kidney was done, after which the left kidney was exposed and connective
and adrenal tissues were gently separated. Next, the kidney was placed in
an acrylic cup and ischemia was induced for 30 min by placing 6-0 nylon
suture under the renal artery and applying hanging weights, to occlude
blood flow. Following 30 min of ischemia, hanging weights were removed
and the kidney was allowed to reperfuse. Mice were given saline, sutured
closed, and allowed to recover for the indicated time points of reperfusion
(typically 4 and 24 h of reperfusion).
Analysis of renal function
To assess kidney function, glomerular filtration rate (GFR) was measured as
previously described (50). Briefly, mice were anesthetized with pentobar-
bital at 20 mg/kg and kept warm to maintain their body temperature using
an anal probe during the entire surgery. Once mice were fully anesthetized,
a catheter was inserted into the jugular vein with a second catheter inserted
into the bladder to collect urine. Next, inulin-FITC (Sigma-Aldrich) was
infused at 800 ml per minute. Blood and urine were collected every 20 min
to measure GFR as described (50, 51).
Parabiosis
Parabiosis surgery was performed as previously described (42, 43).
Briefly, a longitudinal skin incision was made on the flanks of both
C57BL/6NCr (Ly5.2) and B6-Ly5.1/Cr age-and weight-matched female
mice. Their elbows and knees were joined with dissolvable sutures and
the incision was closed with wound clips. Postoperative care included
administration of buprenorphine (Buprenex) for pain control and 5%
dextrose and 0.9% sodium chloride for fluid replenishment. Nutritional
gel packs were provided in each cage and Sulfatrim (sulfamethoxazole/
trimethoprim) was included in the drinking water for the duration of the
experiment. Mice were sacrificed and analyzed 14 d after surgery. The
procedure was approved by the Animal Studies Committee at Washington
University (St. Louis, MO).
Flow cytometric cell analysis
To quantify the number of NK and NKT cells, mice were perfused with PBS
and kidneys were harvested and minced through a 70-mm filter. Digested
tissue was washed with RPMI 1640 and then lymphocytes were purified
using a 36% Percoll gradient (GE Healthcare). Cell were stained in FACS
buffer (PBS, 0.2% FBS, 0.01% sodium azide), anti-FcR blockade CD16/32,
and anti-CD3 PE-Cy7 (145-2C11), anti-NK1.1 PerCP-Cy5.5 (PK136),
anti-NKp46 (29A1.4), and anti-CD45 (30-F11). NK cells were defined as
CD45+CD32NK1.1+ events, with NKT cells defined as CD45+CD3+
NK1.1+ events. For studies analyzing trNK cells, mice were perfused
with 15 ml saline (excluding parabiotic studies and analysis of Tbet2/2
and NFIL-32/2 mice), after which kidney, liver, lung, pancreas, and
uterus were harvested, minced, and mechanically disrupted, followed by
a 1-h enzymatic digestion in collagenase D (1 mg/ml, Roche) at 37˚C.
Cells were then washed in complete RPMI 1640 (10% FCS, 1% penicillin/
streptomycin). Cells were then stained with a mixture of fluorescently-
labeled Abs from eBioscience: anti-CD3 eFluor 450 (145-2C11), anti-CD19
eFluor 450 (ebio1D3), anti–MHC class II eFluor 450 (MS/114.15.2), anti-
CD45 allophycocyanin–eFluor 780 (30-F11), and anti-NK1.1 PerCP-Cy5.5
(PK136); or from BioLegend: anti-NKp46 PE or PE-Cy7 (29A1.4), anti-
CD49b PE-Cy7 (DX5), anti-CD49b (HMa2), anti-TRAIL PE, anti-CD44
FITC, anti-CD160 PE, anti-CD49a PE or allophycocyanin, and anti-AsGM1
Alexa Fluor 647 (poly21460); or from BD Pharmingen: anti-CD49a (Ha31/8).
NK cells were identified as lymphocytes (by forward scatter and side scatter)
that were CD45+, Lineage2 (CD32CD192MHC class II2), and either
NK1.1+ or NKp46+. trNK and cNK cells were identified as either CD49a+
or DX5+, respectively. Anti–AsGM1 Ab staining was done using 0.35 mg
Ab per stain for 30 min. In a subset of studies, cNK cells were defined as
NK cells that expressed CD49b+CD49a2 using the HMa2 clone, instead of
the CD49b-reactive DX5 clone. Note that both Abs recognize CD49b, al-
though the DX5 clone may be less sensitive than HMa2 for cells that ex-
press lower levels of CD49b (52). For NK, trNK versus cNK, and NKT cell
composition after IgG or NK1.1 treatment, mice were treated with either
IgG control Ab or NK1.1 Ab on days23 and21. On day 0, mice were then
subjected to the hanging weight system for 30 min to induce IRI. After 1 d
of reperfusion, kidney was harvested and lymphocytes were purified and
analyzed using flow cytometry after staining as noted above, with NKp46
being the NK cell marker. For parabiotic studies, cells were stained for
CD45.1 (clone A20) and CD45.2 (clone 104) (both from eBioscience).
Gating strategies for flow cytometric analysis are indicated in the figure
legends. Samples were analyzed using a BD LSR II flow cytometer.
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NK cell depletion
For NK1.1 cell–depleting experiments, B6 and CD1d knockout mice
were treated with either 200 mg control anti-mouse IgG2a (Bio X Cell
C1.18.4, mouse IgG2a isotype control) or anti-NK1.1 Ab (Bio X Cell
PK136) on days 23 and 21. For AsGM1-depleting experiments, B6
mice were treated with 800 mg of either rabbit IgG (SouthernBiotech)
or AsGM1 Ab (Wako Pure Chemical Industries) on day 21. On day 0,
mice were then subjected to the hanging weight system for 30 min to
induce IRI. After 1 d of reperfusion, kidney function was measured by
GFR. NK cell depletion was verified by measuring NK cell percentages
(CD45+CD32NKp46+).
Detection of cleaved caspase-3
B6 mice were treated with IgG or NK1.1 or AsGM1 Abs as above. Mice
that received IgG or NK1.1 Abs were exposed to sham (2I) or ischemic
(+I) surgery and allowed to recover for 4 h. AsGM1-treated mice only
received ischemic surgery (+I). At 4 h reperfusion, kidneys were har-
vested, fixed in 4% paraformaldehyde, and paraffin embedded. Five-
micrometer-thick paraffin sections were deparaffinized, and Ags were
unmasked and immunohistochemically stained for cleaved caspase-3
(Cell Signaling Technology, Danvers, MA; rabbit polyclonal, catalog
no. 9661, 1:1000 in TBST plus 1% BSA [w/v]). Sections required Ag
retrieval in BORG solution (Biocare Medical, Concord, CA; high pH;
10 min at 110˚C) in the Decloaking Chamber (Biocare Medical). All
incubations were performed on the autostainer (Benchmark XT; Ven-
tana Medical Systems/Roche, Tucson, AZ) at an operating temperature
of 37˚C. Primary Ab was incubated for 32 min and detected with
a modified iVIEW DAB detection kit (Ventana Medical Systems/Roche).
The iVIEW secondary Ab was replaced with a species-specific polymer
(rabbit ImmPress; full strength; Vector Laboratories, Burlingame, CA;
8 min) and streptavidin-HRP was replaced with diluted rabbit ImmPress
(1:2 dilution in PBS [pH 7.6]; 8 min). All sections were counterstained in
Harris hematoxylin for 2 min, blued in 1% ammonium hydroxide (v/v),
dehydrated in graded alcohols, cleared in xylene, and coverglass mounted
using synthetic resin. Quantitation of caspase-3 immunopositive cells was
determined by gathering the numerical total across the entire kidney
section, at a 320 (0.26 mm2) magnification. Representative images were
chosen based on the ratio of the number of caspase-3+ cells in ischemic
groups versus sham group. Differences between anti-NK1.1 and anti-
AsGM1 groups were corroborated by a second, independent investi-
gator who was blinded to the experimental groups.
Statistical analysis
Data analysis and plotting were done using Prism 5 (GraphPad Software).
Flow cytometric data were analyzed using FlowJo version 10 (Tree Star),
with data displayed as high-resolution pseudocolor dot plots showing
outliers, plotted on a biexponential axis. Statistical analyses were per-
formed using Prism 5, with an unpaired Student t test or one-way ANOVA
with a Bonferroni posttest correction for multiple comparisons. Ex-
perimental values were considered to be statistically different when
p , 0.05.
Results
Kidney cNK cells preferentially express AsGM1 compared with
trNK cells
Recently, two subsets of NK cells were identified in the liver based
on either tissue-retention (trNK) versus systemic circulation (cNK)
(42). Further studies showed that these subsets could be identified
as CD49a+DX52 (trNK) versus DX5+CD49a2 (cNK) in the liver
as well as in multiple other organs (42, 43). Although trNK cells
were identified in multiple organs, the presence of trNK cells in the
kidney has not been reported. To test this, we analyzed NK cells in
the kidney and identified both CD49a+DX52 and CD49a2DX5+
NK subsets (Fig. 1A). In the unmanipulated kidney, CD49a+ NK
cells were a minor but readily detectable fraction (15–20%) of
the NK cell pool (Fig. 1B). To demonstrate that CD49a+ NK cells
in the kidney were tissue-resident, we analyzed these populations
in parabiotic pairs of mice. This analysis demonstrated that
CD49a+ NK cells were present only in the host and not the other
parabiont, indicating that CD49a+ NK cells did not systemically
circulate between the two parabionts (Fig. 1C, 1D). In contrast,
DX5+CD49a2 NK cells were detectable in both parabionts, in-
dicating that DX5+ NK cells were capable of systemic circulation,
exchanging these cells between the two parabionts in the kidney
(Fig. 1C, 1D). The percentage chimerism in the parabiotic mice
was determined by the expression of CD45.1 and CD45.2 in the
spleen (Fig. 1E). These data demonstrate that the kidney contains
both CD49a+ trNK cells and DX5+ cNK cells.
trNK cells and cNK cells have differential expression of multiple
proteins (42, 43). To investigate the cell surface phenotype of
these two subsets in the kidney, we performed an analysis of
proteins involved in NK cell activation and trafficking. These
studies showed that in the kidney, trNK cells had uniform increased
expression of CD44 (an activation and adhesion protein), CD160
(an activation-associated protein), and TRAIL (an apoptosis-
inducing cell surface protein) relative to cNK cells, with a sub-
set of trNK cells also expressing the chemokine receptor CCR2
(Fig. 1F). In contrast, trNK cells had uniformly low expression of
CD62L (an adhesion protein) relative to cNK cells (Fig. 1F). trNK
cells also had reduced expression of two inhibitory receptors
relative to cNK cells, uniformly lacking expression of KLRG1
with a prominent fraction of trNK cells that also failed to express
CD244 (Fig. 1F). Strikingly, kidney trNK cells had reduced ex-
pression of AsGM1 (Fig. 1G), a glycolipid moiety that has been
a target for Ab-mediated depletion of NK cells in vivo (53). These
data identify that trNK cells have a more activated phenotype with
potentially reduced susceptibility to inhibitory signals compared
with cNK cells. They further indicate that trNK cells express
variable levels of AsGM1 and may be differentially susceptible to
AsGM1 Ab-mediated depletion in vivo.
Kidney trNK cells develop independent of NFIL3 and T-bet
We next sought to determine the developmental requirements for
kidney trNK cells. To do this, we investigated the relative frequency
and abundance of trNK and cNK cell subsets in the kidney under
baseline conditions, in mice deficient in either NFIL3, which is
required for cNK cell development (54, 55), or T-bet (Tbx21),
which contributes to NK cell maturation (38) and is required for
the development of liver and skin but not uterine trNK cells
(43). Kidney trNK cells were present at or above levels found in
B6 mice both by total cell number and by frequency in NFIL3-
deficient mice (Fig. 2A, 2B). Conversely, cNK cells were largely
absent from the kidney in NFIL3-deficient mice, consistent with
previous reports identifying NFIL3 as an essential regulator of
cNK cell development (54, 55). trNK cells were also present at
a normal frequency in T-bet–deficient mice, although T-bet–
deficient mice had reduced numbers of NK cells, with ∼50% the
number of trNK cells and only ∼20% the number of cNK cells
relative to B6 mice (Fig. 2A, 2B). AsGM1 was expressed at lower
levels in trNK cells relative to cNK cells in both NFIL3-deficient
and T-bet–deficient mice, consistent with AsGM1 expression
levels observed in trNK cells in wild-type mice (Fig. 2C, 2D).
Whereas differential AsGM1 expression was observed between
trNK and cNK cells in all strains of mice, NFIL3-deficient mice
have reduced AsGM1 expression in cNK cells and fewer AsGM1low
trNK cells than in wild-type mice (Fig. 2C, 2D). These studies
show that kidney trNK cells develop independent of NFIL3 and
Tbet.
AsGM1 is preferentially expressed on cNK cells compared with
trNK cells across multiple strains and organs
Given the broad use of AsGM1 NK cell–depleting regimen on
various strains of mice, we sought to determine whether prefer-
ential expression of AsGM1 on cNK cells was exclusive to the
kidney and B6 mice. To determine whether trNK cells and cNK
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cells had differential expression of AsGM1 in additional tissues
and genetic backgrounds, we analyzed these NK cell subsets in
different strains of mice using NKp46, a common marker for NK
cells (56). Notably, NKp46 is interchangeable with NK1.1 when
identifying trNK and cNK cell subsets in the kidney of B6 mice
(Supplemental Fig. 1).
When we analyzed the relative frequency of cNK and trNK cells
across common inbred strains of mice (B6, NOD, BALB/c, and
FIGURE 1. The kidney contains both cNK and trNK cells characterized by differential AsGM1 expression. B6 mice were perfused with PBS, and kidney
tissue was analyzed for the presence of CD49a+ trNK versus DX5+ cNK cells. (A) Representative flow cytometric analysis to identify NK cells (NK1.1+
CD32CD192MHC class II2) that were either trNK cells (CD49a+DX52) or cNK cells (DX5+CD49a2). (B) Percentage distribution of trNK and cNK cell
subsets in the kidney. (C–E) Negligible exchange of kidney CD49a+DX52 NK cells in parabiotic mice. WT B6 (CD45.2) mice were parabiosed to congenic
B6 (CD45.1) mice. At day 14 after surgery, the spleen and kidney were harvested and flow cytometry was performed. (C) Representative contour plots of
the kidney gated on live CD32CD192NK1.1+ cells followed by a CD45.1 gate (left panels) and CD45.2 (right panels) as indicated for each parabiont. The
percentages of CD49a+DX52 and CD49a2DX5+ cells are indicated in the dot plots. (D) The percentages of CD49a+DX52 and DX5+CD49a2 cells in the
kidney from (C) are shown in the stacked bar graph, which represents eight parabiotic pairs done three independent times. (E) The chimerism in the
parabiotic pairs is measured by the percentage of CD45.1 and CD45.2 expression in the spleen depicted in the stacked bar graph. (F) Representative
expression levels of cell surface proteins comparing trNK (shaded gray) and cNK (open black line) cells, defined as in (A). (G) Representative histogram of
AsGM1 expression for trNK and cNK cell subsets, with quantification of mean fluorescence intensity (MFI) on the right. Data depict mean 6 SEM, with
each data set containing data from three to five mice per group from independent experiments. *p , 0.05 as determined by unpaired t test.
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129), we found that trNK frequency was relatively comparable
across different backgrounds, with NOD mice showing a slightly
increased trNK frequency in some organs (Fig. 3A). Whereas
certain organs consistently had low frequencies of trNK cells
(spleen and lung), other organs uniformly had elevated frequen-
cies of trNKs (liver, kidney, and pancreas) regardless of back-
ground (Fig. 3A, Supplemental Fig. 1B, 1C). The frequency of
uterine trNK cells varied dramatically between different strains of
mice, with BALB/c and 129 strains of mice having low frequen-
cies of trNK cells compared with B6 and NOD mice (Fig. 3A).
Next, we analyzed the expression of AsGM1 on cNK and trNK
cells in various organs and genetic backgrounds. cNK cells uni-
formly expressed high levels of AsGM1 across all organs analyzed,
regardless of strain (Fig. 3B, Supplemental Fig. 1D). In contrast,
trNK cells had differential expression of AsGM1, with most trNK
cells expressing only low levels of AsGM1 in the kidney, spleen,
liver, and lung (Fig. 3B). Whereas a subset of trNK cells had
comparable expression of AsGM1 relative to cNKs (e.g., in the
liver of B6 mice), the only instance where trNK cells uniformly
expressed high levels of AsGM1 comparable to cNK cells was in
the uterus of some strains of mice (B6 and 129) (Fig. 3B).
Analysis of NK cell subsets using AsGM1 as a primary parameter
relative to either CD49a or DX5 further identified CD49a+ trNK
cells with low, intermediate, and high levels of AsGM1 expres-
sion, varying by organ and genetic background (Supplemental
Fig. 2). Taken together, these data show that cNK cells uni-
formly express high levels of AsGM1 and that trNK cells
contain a phenotypically heterogeneous population characterized
by variable, but reduced, expression of AsGM1 across multiple
organs and strains of mice.
AsGM1 Ab treatment preferentially depletes cNK cells in B6
and BALB/c mice and enhances the relative frequency of trNK
cells
Anti–AsGM1 Abs have been commonly used to deplete NK cells
across diverse genetic backgrounds. Our data indicate that although
AsGM1 is uniformly expressed at a high level in cNK cells, it is
variably expressed in trNK cells, with many trNK cells expressing
low levels of AsGM1. We next sought to determine whether the
presence of AsGM1low trNK cells may reduce the susceptibility of
trNK cells to be depleted by AsGM1 Ab treatment in B6 mice.
AsGM1 Ab treatment resulted in a pronounced decrease in the fre-
quency and number of total NK cells across multiple organs, con-
sistent with the overall higher frequency of cNK cells relative to trNK
cells (Fig. 4A, 4B, Supplemental Fig. 3A). Whereas AsGM1 treat-
ment reduced the number of both cNK and trNK cells (Supplemental
Fig. 3B), the magnitude of depletion between cNK cells and trNK
cells profoundly differed. Indeed, when we measured the relative
frequency of cNK cells and trNK cells, we found that AsGM1 Ab
treatment resulted in a pronounced shift in the relative frequency of
cNK cells and trNK cells within the kidney, liver, lung, and spleen
(Fig. 4A, 4B). These data indicate that in B6 mice trNK cells have
reduced susceptibility to AsGM1-based Ab depletion.
Whereas AsGM1Ab depletion is used in B6mice, it is often used
as a method to validate results obtained by NK1.1 Ab depletion. In
contrast, certain strains of mice (e.g., BALB/c) do not express the
FIGURE 2. Kidney CD49a+DX52 NK
cells develop independent of NFIL3 and
T-bet. The kidney was isolated from WT,
NFIL3 KO, and T-bet KO mice, stained,
and analyzed by flow cytometry. (A) Rep-
resentative dot plots were gated on live
CD45+CD32CD192NK1.1+ and show the
percentage of CD49a and DX5 expres-
sion. (B) The bar graphs depict the number
(left panel) and percentage (right panel)
of live CD45+CD32CD192NK1.1+ that
express CD49a and DX5 in the kidney of
WT, NFIL3 KO, and T-bet KO mice. (C)
The histograms indicate the expression
of AsGM1 on gated CD45+CD32CD192
NK1.1+CD49a+ (shaded gray histogram,
trNK) and CD45+CD32CD192NK1.1+
DX5+ (black line histogram, cNK). (D)
The graph represents the mean fluo-
rescence intensity (MFI) of AsGM1 on
CD49a+ and DX5+ on NK cells of WT
(s), NFIL3 KO (d), and T-bet KO ())
mice. Experiments were performed three
independent times. *p , 0.05 as deter-
mined by unpaired t test between trNK
and cNK cells within the same geno-
type. KO, knockout.
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PK136-reactive NK1.1 allele, such that AsGM1 Ab is the primary
method to test the role for NK cells in vivo (23). Given that BALB/c
mice also contain AsGM1low trNK cells, we next tested the se-
lectivity of AsGM1 Ab depletion on cNK and trNK cells in this
strain. AsGM1 Ab treatment again resulted in a large reduction in
the frequency of NK cells and an overall decrease in cNK and
trNK cell numbers (Supplemental Fig. 3A, 3C), with AsGM1 Ab-
treated mice showing a notable skewing in the relative frequency
of trNK cells in the liver, lung, and spleen (Fig. 4C, 4D). In total,
these data indicate that AsGM1 Ab treatment preferentially
depletes cNK cells, resulting in a relative sparing of trNK cells
across multiple organs and two common inbred strains of mice.
trNK cells and cNK cells in IRI of the kidney
NK cells have been implicated in IRI in the kidney, but the role of
trNK and cNK cells is unclear (45–47). We sought to characterize
the dynamics of trNK cells and cNK cells during ischemic injury
in the kidney by employing the hanging weight system of IRI,
a well-established model of AKI (50). In mice subjected to 30 min
of ischemia, kidney function as measured by GFR rapidly de-
clined within 4 h after reperfusion, with maximal loss of kidney
function occurring by 24 h (Fig. 5A). We next determined the total
number of NK cells at 4, 8, and 24 h after reperfusion and found
that there were no significant differences in the total number of
NK cells present in the kidney following this acute ischemic injury
(Fig. 5B). Given that NK cell numbers did not change dramati-
cally, we next determined whether there were changes in the
relative distribution of trNK and cNK cells or their activation
phenotype during this acute time course. At 4 and 24 h after
reperfusion, there were no changes in the relative distribution of
trNK and cNK cells in the kidney (Fig. 5C, 5E). Furthermore,
when we analyzed the activation status of trNK cells and cNK
FIGURE 3. cNK and trNK cells have differential expression of AsGM1 across multiple organs and genetic backgrounds. B6, NOD, BALB/c, and 129
mice were analyzed for the frequency of trNK and cNK cell subsets and the AsGM1 expression in these subsets. (A) Frequency of trNK and cNK cells was
determined in multiple organs in various strains based on NK cells, defined as CD32CD192NKp461. (B) AsGM1 expression in trNK (shaded gray) and
cNK (open black line) cells, with organ analyzed indicated at the top of each column, and genetic background indicated at the left of each row. Each data set
has three to five mice per group from independent experiments.
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cells during IRI, we found that trNK cells expressed higher levels
of CD160, CD44, and TRAIL than did cNK cells at both 4 and
24 h, in both the naive (sham) and ischemic kidney, with no dis-
cernable difference in either NK cell subset following ischemic
injury (Fig. 5D, 5F). These distinct phenotypes mirrored differ-
ences observed in trNK and cNK cells in the steady-state. Taken
FIGURE 4. AsGM1 Ab treatment preferentially depletes cNK cells in B6 and BALB/c mice to enhance the relative frequency of trNK cells. B6 (A and
B) and BALB/c (C and D) mice were treated rabbit IgG or AsGM1 Ab day 21, and organs were harvested 1 d later and analyzed for trNK and cNK cells
(defined as NKp461 cells). (A) Representative dot plots of NK cell subsets in B6 kidney, liver, lung, and spleen after IgG (top row) or AsGM1 (bottom row)
treatment. (B) Frequency distribution of NK subsets in B6 mice across multiple organs based on CD49a and CD49b expression treated with IgG or AsGM1
Ab. (C) Representative dot plots of NK cell subsets in BALB/c kidney, liver, lung, and spleen after IgG (top row) or AsGM1 (bottom row) treatment. (D)
Change in frequency distribution of NK subsets in BALB/c mice from multiple organs based on CD49a and CD49b expression treated with IgG or AsGM1.
Each data set has three to six mice per group from independent experiments. *p , 0.05 as determined by unpaired t test, comparing the frequency of either
cNK or trNK in IgG- versus AsGM1 Ab–treated mice.
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together, these data suggest that trNK and cNK cells have a rela-
tively stable number and cell surface phenotype during acute
ischemic kidney injury, with trNK cells showing evidence for a
heightened basal activation state.
NK1.1-depleting Ab protects mice from kidney dysfunction
during IRI
The use of anti–NK1.1 Ab as a depleting strategy for NK and
NKT cells is well established in the field. Whereas anti-NK1.1–de-
pleting studies have been shown to be protective in some studies of
ischemic kidney injury (47), the role of NK cells in the hanging
weight model of kidney injury remains to be elucidated. To test this,
B6 mice were treated with either isotype or anti-NK1.1–depleting Ab
(administered on days 23 and 21), subjected to IRI on day 0, and
allowed to recover for 1 d. Depletion of NK cells (CD45+CD32
NKp46+) was confirmed in the kidney by flow cytometry (Fig. 6A),
with NK1.1 Ab treatment resulting in an equivalent depletion of both
cNK and trNK cells (Fig. 6B, 6C). Whereas isotype-treated animals
subjected to IRI had a pronounced impairment in kidney function as
measured by GFR, anti-NK1.1–treated mice showed a clear im-
provement in kidney function, with GFR values nearly restored to
values measured from sham, nonischemic mice (Fig. 6D).
The NK1.1 Ag is expressed by both NK and NKT cells, both
of which have been implicated in AKI (45, 47, 57, 58). To test the
role of NKT cells in this model, we quantified the number of
NKT cells (CD45+CD3+NK1.1+) at 4, 8, and 24 h after IRI and
found no significant changes in total numbers (Supplemental Fig.
4A, 4B). Importantly, when comparing the number of NK and
NKT cells in the ischemic kidney, NK cells were much more
abundant than NKT cells (Supplemental Fig. 4C).
Given that the NK1.1 Ab can deplete both NK and NKT cells, we
sought to test the impact of NK1.1 Ab treatment on mice genetically
FIGURE 5. IRI in the kidney does not profoundly alter phenotype of trNK and cNK cells. B6 mice were subjected to either sham surgery (open bars) or
30 min of ischemia (filled bars) and analyzed as described. (A) After 4, 8, and 24 h of reperfusion, kidney function was measured by GFR. (B) B6 mice were
subjected to IRI and after 4, 8, and 24 h of reperfusion, NK cells were quantified using Percoll purification and analyzed by flow cytometric analysis by
staining for CD45+CD32NK1.1+ expression. (C) B6 mice were subjected to sham or 30 min of ischemia and analyzed for the frequency of trNK and cNK
cells at 4 h after IRI. (D) Flow cytometric analysis of mean expression of activation markers on trNK versus cNK cells at 4 h after IRI in the kidney. Each
data set has four to six mice per group. (E) B6 mice were subjected to sham or 30 min of IRI surgeries and analyzed for the frequency of trNK and cNK cells
at 24 h after IRI. (F) FACS analysis of mean expression of activation markers on trNK versus cNK at 24 h after IRI in the kidney. Each data set has four to
six mice per group from independent experiments. *p , 0.05 as determined by unpaired t test, comparing either values from the same time point between
sham and ischemia (A), or by one-way ANOVA with significance indicated between cNK and trNK (D and F).
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deficient in NKT cells (e.g., Ja18- or CD1d-deficient mice).
Whereas mice deficient in the TCR gene segment Ja18 have
a deficit in NKT cells, recent studies have shown that these mice
also have major alterations in TCR repertoire (59). Based on
this, we tested CD1d1 3 CD1d2–deficient mice, which are de-
fective in NKT cell development, without other known defects
in lymphocyte development (60, 61). As expected, anti–NK1.1
Ab treatment profoundly depleted NK cells in CD1dKO mice
(Supplemental Fig. 4D). Whereas isotype-treated CD1dKO mice
subjected to ischemia showed decreased GFR, similar to wild-
type mice, anti–NK1.1 Ab treatment significantly improved
GFR in both CD1dKO and wild-type ischemic mice (Fig. 6D).
Based on these data, we conclude that the primary protective
effect of anti–NK1.1 Ab treatment results from depletion of NK
cells, not NKT cells.
AsGM1 preferentially ablates cNK cells, showing that trNK
cells promote AKI
Whereas the above data identify NK cells as mediators of ischemic
injury, they do not discriminate between the relative contributions
of trNK and cNK cells, because NK1.1 Ab treatment equivalently
depletes both NK cell subsets. Given the differential expression of
AsGM1 on trNK and cNK cells in the kidney, and their differ-
ential susceptibility to AsGM1 Ab depletion, we hypothesized that
AsGM1 Ab treatment may allow us to dissect the relative con-
tributions of trNK and cNK cells to ischemic kidney injury. To test
this, we treated B6 mice with anti–AsGM1 Ab depletion and
subjected these mice to either sham (nonischemia) or ischemic
injury. Anti–AsGM1 Ab treatment resulted in a profound reduc-
tion of kidney NK cells in these mice, comparable to the magni-
tude of depletion observed following anti–NK1.1 Ab treatment
(compare Figs. 6B and 7A). Consistent with our previous data,
anti–AsGM1 Ab resulted in a prominent increase in the relative
frequency of trNK cells in the ischemic kidney (Fig. 7A, 7B).
Next, we tested the consequence of Ab treatment of kidney
injury and function. First, we examined the consequence of anti–
NK1.1 and anti–AsGM1 Ab treatment on the early induction of
apoptosis after ischemic injury, measured by active caspase-3
staining at 4 h after reperfusion. These studies showed that anti–
NK1.1 Ab-injected mice had a significantly decreased number
of apoptotic cells relative to anti–AsGM1 Ab-injected mice
(Supplemental Fig. 4E–I). To investigate the consequence of these
Abs on kidney function at 24 h reperfusion, we measured kidney
function by GFR, a gold standard for kidney function, comparing
FIGURE 6. NK1.1 Ab treatment effectively depletes trNK and cNK cells in the kidney and attenuates kidney damage. B6 mice were treated with IgG or
NK1.1 Ab on days 23 and 21 and subjected to IRI on day 0 and analyzed at day 11. (A) The frequency of NK cells in the kidneys of B6 mice that were
treated with IgG or NK1.1 Ab and subjected to sham (2I) or IRI (+I) surgeries at 1 d after reperfusion. (B and C) B6 ischemic kidneys treated with either
IgG or NK1.1 Ab were analyzed by flow cytometric analysis for distribution of trNK versus cNK cells, with frequencies plotted in (C). (D) Quantification of
GFR in B6 and CD1d KO mice that received either IgG or NK1.1 Ab treatment in sham (2I) or ischemic (+I) conditions. Each data set has three to six mice
per group from independent experiments. *p , 0.05 as determined by unpaired t test (C), comparing IgG- and NK1.1-treated mice or by one-way ANOVA
with a Bonferroni posttest correction for multiple comparisons (A and D).
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isotype-, anti–AsGM1 Ab-, and anti–NK1.1 Ab-injected mice.
Strikingly, whereas anti–NK1.1 Ab treatment conferred protec-
tion, anti–AsGM1 Ab treatment failed to protect mice from IRI
despite a similar reduction in overall NK cell percentages (Fig.
7C). Given that anti-AsGM1 poorly depletes trNK cells, in con-
trast to anti–NK1.1 Ab treatment, these data identify that trNK
cells are sufficient to promote IRI in the kidney.
Discussion
NK cells are sentinels in the immune response that rapidly detect
changes in the cellular environment to produce cytokines and to
induce target cell apoptosis. Whereas NK cells have been impli-
cated in diverse responses (e.g., virus infection, DNA damage,
cellular transformation, and IRI), a common trigger of NK cells is
the detection of cellular stress, which either increases NK cell
activating ligands or decreases NK cell inhibitory ligands (62).
Recent data indicate that NK cells not only circulate, but that
a subset of trNK cells are retained in situ (42, 43). In the present
study, we hypothesized that trNK cells function as important
mediators in IRI by being poised for immediate response to tissue
injury. To test this, we studied this process in the kidney and found
that 1) trNK cells are present in the kidney; 2) trNK cells in
the kidney, and other tissues, have reduced expression of AsGM1,
a common target in NK cell depletion studies; and 3) anti–AsGM1
Ab depletion preferentially spares kidney trNK cells. Based on
this knowledge, we directly compared how two different methods
of NK cell depletion that differed in their ability to deplete trNK
cells impacted IRI. Our studies show that although trNK cells are
numerically minor, these cells are potent mediators of ischemic
tissue injury.
NK cells are regulated by the relative engagement of activating
and inhibitory NK cell receptors by their respective ligands on
neighboring cells (62). A common theme of these responses is that
cellular stress in target cells can either increase activating ligands
(e.g., MICA in humans and Rae-1 in mice) or decrease inhibitory
receptor ligands (e.g., MHC class I). In this context, IRI, the
process of transient oxygen insufficiency (i.e., hypoxia) to a tissue,
is associated with the induction of cellular stress markers such as
MICA (in humans) and Rae-1 (in mice), which are potent acti-
vating ligands for activating NK cells (45, 63–65), placing NK
cells as central mediators of ischemic tissue injury.
In the present study, we examined the role of NK cells in IRI by
using a mouse model of ischemic AKI, a common human pathology
characterized by ischemia that can result from various etiologies,
including diabetes, major surgery, sepsis, and drug toxicity (44).
Whereas previous studies highlighted the importance of NK cells in
FIGURE 7. AsGM1 Ab preferentially depletes cNK cells, showing that trNK cells promote AKI. B6 mice were treated with IgG or AsGM1 Ab on day21
or treated with NK1.1 Ab on days23 and21 and then subjected to sham (2I) or IRI (+I) surgeries on day 0 and analyzed at day +1. (A) Representative dot
plots of kidneys 24 h after IRI from B6 mice that were treated with IgG or AsGM1 Ab and analyzed for the frequency of NKp46+ NK cells (left) and the
frequency of trNK and cNK cells in either IgG-treated (top) or AsGM1-treated (bottom) mice. (B) Quantification of the frequency of trNK and cNK cells
after IgG or AsGM1 Ab treatment in ischemic kidneys. (C) B6 mice treated with IgG, AsGM1, or NK1.1 Ab were given sham (2I) or IRI (+I) surgeries and
GFR was measured 1 d after surgery. Each data set has five to eight mice per group from independent experiments. *p , 0.05 as determined by unpaired
t test (B), comparing IgG- and AsGM1-treated mice or by one-way ANOVA with a Bonferroni posttest correction for multiple comparisons (C).
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ischemic AKI using patch-clamping models of AKI, which are
associated with intrarenal coagulation (45–47), the role of cNK and
trNK cells in ischemic injury had not yet been studied.
Our identification of trNK cells as an important cell type in
mediating IRI damage emphasizes how local NK cell responses can
trigger tissue injury in the absence of NK cell recruitment. It is also
notable that trNK cells express low levels of two inhibitory
receptors, KLRG1 and CD244, suggesting that trNK cells may have
an increased propensity toward cytotoxicity resulting from de-
creased inhibitory signaling. Importantly, KLRG12 NK cells have
been reported in other studies that were not cNK cells (CD32
NK1.1+DX52), suggesting that in some contexts, absence of
KLRG1 may be another marker for trNK cells (66–68). Addi-
tionally, CCR2 was exclusively on a subset of CD49a+ trNK cells
in unmanipulated and ischemic kidney (data not shown), consis-
tent with reports of CCR2+ NK cells during lung inflammation
(39); these data suggest that trNK cells may play a role in the
CCL2/CCR2 chemokine axis important for monocyte recruitment.
Note that whereas our studies highlight a role for trNK cells in the
early stages of acute ischemic injury, at this time we have not
focused on later stages of ischemic injury when recruitment of
cNK cells may further enhance tissue damage (29).
AsGM1 was identified as a NK cell marker .30 y ago (69, 70),
and depleting regimens using anti-AsGM1 Ab have been critical
in showing the requirement of NK cells in diverse experimental
settings (71–76). Indeed, whereas AsGM1 Ab depletion is not
uniquely restricted to NK cells (e.g., see Ref. 22), this method
remains in use today, both to deplete NK cells in mouse strains
that do not express the PK136-reactive NK1.1 allele (e.g., BALB/c),
and as a complementary approach to anti–NK1.1 Ab studies in
NK1.1-expressing mice (e.g., B6).
Our data indicating differential expression of AsGM1 on subsets
of trNK cells provide a new level of consideration in the use of
AsGM1 Ab depletion. First, by comparing and contrasting the
impact of AsGM1- and NK1.1-based depletion methods on trNK
and cNK cells and IRI, our studies illustrate a new approach to
distinguish trNK and cNK cell functions in vivo. Second, our data
identify an unanticipated heterogeneity of AsGM1 expression
among trNK cells. Whereas AsGM1 Ab significantly depletes cNK
cells, this Ab regimen is unable to deplete at least a subset of trNK
cells. As such, AsGM1 Ab results in incomplete depletion of trNK
cells, an especially important consideration when studying tissues
enriched in trNK cells (e.g., kidney, liver, pancreas, and uterus).
Notably, a simple approach to understanding the utility and lim-
itations of AsGM1 Ab depletion studies can be obtained by ana-
lyzing AsGM1 expression on cNK and trNK cells in the organ of
interest. Our studies also emphasize the importance of analyzing
NK cell depletion studies not only in the blood (which lacks trNK
cells) but also in situ. Notably, analysis of NK cell depletion in the
spleen and/or peripheral blood (which is devoid of trNK cells) or
use of DX5 as an NKmarker (which is not expressed on trNK cells)
may significantly overestimate the efficiency of Ab-based depletion
in various tissues by failing to consider trNK cell reservoirs. Given
these caveats, we consider it likely that the functional contribution
of trNK cells remains underappreciated, especially in studies based
solely on AsGM1-depleting Abs.
Depending on the organ and strain of mouse, trNK cells rep-
resent a sizable fraction of the NK cell pool with the long-term
capacity to monitor and influence tissue function. Although the
function of trNK cells remains an active area of investigation, trNK
cells appear to have unique capabilities, demonstrated both by their
ability to directly facilitate delayed type hypersensitivity reactions
(42) and by their unique cytokine and cytolytic profile (43). Given
that trNK cells are retained in tissue and poised for activation, our
data identify trNK cells as an early player in the IRI response in
the kidney. Although future studies are required to determine the
functional mechanisms by which trNK cells promote IRI, it is
clear that trNK cells are sufficient to induce tissue damage even
after AsGM1 Ab depletion reduced the overall number of trNK
cells.
Based on these data, we hypothesize that trNK cells may be
major mediators of ischemic injury in multiple organs. Curiously,
trNK cells have tissue-specific differences in terms of their de-
velopment, with T-bet–dependent liver and skin trNK cells, in
contrast to T-bet– and NFIL3-independent kidney and uterine
trNK cells (43). Although developmental and functional com-
monalities between kidney and uterine trNK cells remain to be
further explored, it is notable that uterine trNK cells appear to
regulate spiral artery arborization in the uterus (77). It is tempt-
ing to speculate that kidney trNK cells may also be involved
in vascular changes, whether during ischemic injury or during
development.
An important future goal in understanding trNK cells will be to
determine the functional heterogeneity of trNK cells, both within
an individual tissue and between different tissue types. Based on
our studies, we propose that AsGM1 expression can serve as one
additional parameter that may provide insights into trNK cell
subsets. Examples of this include the heterogeneity of AsGM1
expression within trNK cells in the kidney, with some cells
expressing little to no AsGM1 in contrast to other AsGM1high trNK
cells. One notable exception to the heterogeneous, reduced ex-
pression of AsGM1 on trNK cells is in uterine trNK cells in B6
mice, consistent with an increasing literature suggesting unique
developmental and functional properties of uterine NK cells (43,
77, 78). Whereas the biologic consequence of differential ex-
pression of AsGM1 remains unknown, in the future it will be
important to determine whether AsGM1 serves as an indicator of
trNK maturation, localization, and/or directly shapes the func-
tionality of trNK cells.
trNK cells are a recently described subset of NK cells, whose
functions remain an active area of investigation. By studying trNK
cells in the kidney and other organs, our data identify an unan-
ticipated differential expression of AsGM1 on trNK cells in
multiple organs and strains of mice. These data emphasize that
AsGM1 expression may provide a powerful new approach by
which to gain fundamental new insights into NK cell development
and function. Furthermore, to our knowledge, our studies provide
the first evidence that trNK cells play a central role in ischemic
tissue injury.
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